Eli Lilly Strikes Deal Worth Up to $1.5 Billion for Blood Cancer Biotech
Fact checked by NewsPlainVerified by NewsPlain: confirmed by at least two named sources
Brief
Eli Lilly agreed on Nov. 16 to acquire Calytrix Bio in a cash deal worth as much as…
Keep reading with NewsPlain Premium
Get the full brief, the full story, what's confirmed, what's still unclear, why it matters, and every source.
4 confirmed facts and 3 sources behind this story.